"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in this website by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 3 | 1 | 4 |
| 2000 | 1 | 2 | 3 |
| 2001 | 0 | 4 | 4 |
| 2002 | 2 | 2 | 4 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 2 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 3 | 5 |
| 2007 | 3 | 2 | 5 |
| 2008 | 9 | 2 | 11 |
| 2009 | 3 | 2 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 3 | 6 |
| 2012 | 5 | 5 | 10 |
| 2013 | 3 | 5 | 8 |
| 2014 | 10 | 0 | 10 |
| 2015 | 5 | 2 | 7 |
| 2016 | 4 | 0 | 4 |
| 2017 | 5 | 1 | 6 |
| 2018 | 5 | 1 | 6 |
| 2019 | 4 | 0 | 4 |
| 2020 | 4 | 0 | 4 |
| 2021 | 3 | 1 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 2 | 2 | 4 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles.
-
Dendritic cell-derived exosomes induce monocyte antigen-presentation and immune amplification in neoantigen vaccine therapy. Front Immunol. 2025; 16:1565696.
-
Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Front Immunol. 2025; 16:1571182.
-
mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors. J Immunother Cancer. 2025 Mar 25; 13(3).
-
Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1ß Secretion and T Cell Adjuvanticity. J Med Chem. 2024 Sep 12; 67(17):14974-14985.
-
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e433330.
-
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024 Apr; 30(4):1013-1022.
-
Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. J Immunol. 2024 01 15; 212(2):188-198.
-
Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity. Biomaterials. 2023 05; 296:122062.
-
Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells. J Immunother Cancer. 2023 02; 11(2).
-
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients. Melanoma Res. 2022 04 01; 32(2):88-97.